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Basic mechanism of action cell relaxation. In vascular smooth muscle, the mech-X/f ., . . , . . , . . anism by which cAMP causes vasodilatation is not Milrinone, an analogue of amnnone, is a bipyn-.
. ' used load-independent end-systolic indices of contractility to demonstrate that intravenous bolus doses of milrinone (30,45 and 60 fig kg" 1 ) caused a dose-related increase in several indices of contractility. In addition, it was demonstrated that milrinone produced progressive decreases in total systemic resistance and left ventricular end-systolic wall stress, actions which are indicative of a vasodilator effect.
An increase in +dP/dt has also been observed following oral administration of milrinone. In 12 patients with moderate congestive heart failure, Timmis et al. [7) showed that a 5 mg oral dose of milrinone significantly increased left ventricular maximum +dP/dt (+11%) and dP/dt/P (+68%), the latter being an isovolumic index which is relatively less affected by concomitant changes in loading conditions.
These investigators also demonstrated that the left ventricular end-systolic pressure/dimension relationship was significantly increased by oral administration of milrinone, further supporting a positive inotropic effect of the drug. Piscione et al.' 8 ' likewise found that an oral dose of milrinone caused a significant (15%) increase in +dP/dt, a 33% increase in V max , and a 50% increase in V ce (velocity of contractile elements). It should be noted that observations regarding +dP/dt may be affected by changes in heart rate, arterial pressure and left ventricular cavity dimensions. Decreases in any of these parameters may result in a decrease in +dP/dt, and, conversely, increases may result in an increase in +dP/dt. Because milrinone is a potent vasodilator which decreases both the arterial pressure and the left ventricular preload, a direct positive inotropic effect of the agent might be expected to be partially or totally obscured by the counterbalancing effects of vasodilatation. This counterbalancing effect would be most pronounced in patients with a markedly reduced filling pressure who are, therefore, on the relatively steep portion of the left ventricular function curve.
Observations on the dose-response relationship of the +dP/dt response to milrinone support this point of view' 9 '. In 14 patients with moderate to severe congestive heart failure, incremental bolus doses of milrinone (12.5, 25 and 50 ng kg" 1 ) resulted in an incremental increase in +dP/dt for the entire group. However, in three of the patients +dP/dt increased only with the first two doses, and then fell substantially with the next higher dose. In these three patients, the highest dose of milrinone resulted in a marked decrease in left ventricular end-diastolic pressure from 25 to 6 mmHg. In the other 11 patients who continued to show an increase in +dP/dt, the decrease in left ventricular end-diastolic pressure was much smaller, from a mean of about 27 mmHg to a mean of 17 mmHg. Because it is highly likely that the higher dose of milrinone would exert a similar or greater positive inotropic effect than the lower doses, the most likely explanation is that in the three patients who showed a marked decrease in leftventricular end-diastolic pressure, the reduction in preload obscured the direct positive inotropic effect of the drug.
Although a positive inotropic effect of milrinone is well supported by several studies, the relative contribution of the drug's positive inotropic versus vasodilator effects to its overall net haemodynamic action remains unclear. As an approach to this issue, we have utilized the direct intracoronary infusion of the drug to patients with congestive heart failure' 1011 '. Because coronary artery blood flow is only approximately 4-6% of total cardiac output, it is possible to infuse very small quantities of drug into the coronary artery and yet achieve therapeutic drug levels in the myocardium. As a result of the small intracoronary dose, there is little systemic accumulation of drug, particularly if infusion periods are kept brief.
For this technique, a 7-Fr L-4 Judkins catheter is placed in the left main coronary ostium as if for coronary angiography. The catheter is perfused continuously with heparinized saline solution to prevent clot formation. A micromanometer-tipped catheter is placed in the left ventricle to measure pressure and to allow determination of +dP/dt. Cardiac output is determined by the Fick method. The haemodynamic effects of a drug infused by this method can be ascribed to the agent's direct myocardial effects, plus any indirect systemic action due to a change in myocardial function. The major advantage of this approach is that the effects of the agent on arterial pressure and left ventricular filling pressures are minimized or eliminated, and, therefore, left ventricular +dP/dt can be used as a convenient measure of changes in the left ventricular contractile state.
Intracoronary infusion of milrinone results in a dose-related increase in +dP/dt. This effect is associated with a substantial improvement in leftventricular pump function, as reflected by increases in stroke volume and stroke work, and by small decreases in right and left heart filling pressures (Fig.  2) . At an infusion rate of 50 ^g min" 1 which results in a predicted coronary artery drug concentration that is in the therapeutic range, + dP/dt is increased by 21 %, the stroke volume index is increased by 18%, and the stroke work index is increased by 21%. Interestingly, this effect is associated with a significant (-17%) decrease in the left ventricular end-diastolic pressure (Fig. 2) . This effect may be due to an improvement in the forward pump function, but is also consistent with the possibility of a direct lusitropic action on the myocardium' 12 '. Intracoronary drug infusion also results in a small, but consistent decrease in heart rate. The decrease in heart rate is associated with a decrease in plasma noradrenaline, and appears to reflect a reflex withdrawal of sympathetic tone, which is presumably a consequence of improved left ventricular pump function.
Vasodilator action of milrinone
Although milrinone exerts a potent direct vasodilator effect in vitro, the relevance of this action to patients with congestive heart failure cannot be assumed. This issue has been approached directly by Cody et a/.' 13 ', who evaluated the effect of a direct brachial artery infusion of milrinone on forearm blood flow measured by impedance plethysmography in patients with moderate to severe congestive heart failure. By infusing milrinone directly into brachial artery, it was possible to achieve therapeutic concentrations of milrinone in the forearm circulation, in the absence of significant drug accumulation. For example at brachial infusion rates of 10 and 20 nĝ min" 1 per 100 ml forearm volume, therapeutic milrinone concentrations of 223 and 298 ng ml" 1 were achieved in the forearm circulation, whereas there was no significant accumulation of drug in the systemic circulation. Thus, using this technique, Cody et al. were able to draw conclusions regarding the direct effect of milrinone on the forearm vasculature. Since infusion of milrinone into the brachial artery caused a significant increase in forearm blood flow and a significant decrease in forearm vascular resistance, it can be concluded that therapeutic levels of milrinone result in significant direct vasodilatation in patients with congestive heart failure.
We have used two approaches to evaluate the relative contribution of vasodilatation to the overall haemodynamic effect of milrinone in patients with Figure 2 Haemodynamic effects of intracoronary infusion of milrinone at a rate of 50/ig min" 1 to 11 patients with congestive heart failure. HR, heart rate; MAP, mean arterial pressure (mmHg); SVR, systemic vascular resistance (dyn s cm" 5 ); LVEDP, left ventricular end-diastolic pressure (mmHg); +dP/dt, left ventricular peak +dP/dt (mmHg s" 1 ); SVI, stroke volume index (ml beat" 1 m" 2 ); SWI, stroke work index (g min" 1 m" 2 ). (Reproduced, with permission, from reference 10.)
congestive heart failure. First, the haemodynamic effects of several doses of milrinone and nitroprusside were compared in the same group of patients with moderate to severe congestive heart failure' 5 '. Under these circumstances, it was possible to match the infusion rates of milrinone and nitroprusside for similar reductions in arterial pressure and left ventricular end-diastolic pressure, thereby using nitroprusside to approximate the vasodilator effects of milrinone. The increase in the stroke work index caused by milrinone was significantly greater than that caused by nitroprusside. Thus, although vasodilatation could account for a substantial portion of milrinone's effect on the left ventricular pump function, it could not account for the entire action. The difference between nitroprusside and milrinone presumably reflects the positive inotropic action of the latter.
As a second approach to this issue, we compared the effects of intracoronary and intravenous milrinone infusion' 10 '. In eight patients with moderate to severe congestive heart failure, intracoronary milrinone infusion (at a rate of 50//g min" 1 ) was followed immediately by an intravenous bolus of milrinone (75 Hg kg" 1 )-Since both routes of administration were predicted to result in therapeutic drug levels in the myocardium, we reasoned that the haemodynamic effect of intravenous drug would be a reflection of both the positive inotropic action and the vasodilator action of the drug, whereas the effect of intracoronary drug would reflect only the myocardial action. As anticipated, intracoronary administration of milrinone resulted in increases in left ventricular +dP/dt, and stroke volume and stroke work indices, and small decreases in right atrial and left ventricular end-diastolic pressures, whereas intracoronary drug caused no decrease in the mean arterial pressure or the systemic vascular resistance. Subsequent intravenous administration of milrinone produced substantial decreases in the mean arterial pressure and the systemic vascular resistance, further marked decreases in right atrial and left ventricular enddiastolic pressures, and further significant increases in stroke volume and stroke work indices (Fig. 3) . From this type of analysis, it appears that both the positive inotropic and vasodilator actions of milrinone contribute significantly to the drug's net haemodynamic effect. Precise quantification of the relative contributions of these two actions should be avoided, because it is unlikely that the experimental condi- Figure 3 The comparative haemodynamic effects of intracoronary infusion of milrinone at a rate of 50 n% min" 1 (ICM) and the subsequent infusion of intravenous milrinone in a dose of 75 /xg kg" 1 (IVM) to eight patients with congestive heart failure. (Reproduced, with permission, from reference 10.) tions allowed a precise matching of the positive inotropic effects of intracoronary and intravenous drug. Nevertheless, it is reasonable to conclude that the positive inotropic and vasodilator actions of the agent contribute approximately equally to the overall effect on haemodynamic function.
Reflex haemodynamic effects of milrinone
In congestive heart failure there is substantial activation of the sympathetic nervous system. The level of sympathetic nervous system tone is modulated by arterial baroreceptors, low-pressure receptors in the heart, and possibly, left ventricular receptors. Consequently, changes in heart size, pressure and/or function can affect the level of sympathetic nervous system activity, which, in turn, may indirectly affect vascular tone and/or myocardial performance. As noted previously, intracoronary milrinone infusion results in significant decreases in plasma noradrenaline and heart rate, presumably indicative of reflex sympathetic withdrawal. In order to evaluate the possible effect of reflex sympathetic withdrawal on vascular tone, we have studied forearm blood flow and venous capacitance by plethysmography during intracoronary milrinone infusion' 14 '. We found that intracoronary administration of milrinone, when infused at a rate that substantially improves left ventricular pump function, has no significant effect on forearm vascular resistance. However, venous capacitance, a measure of venous tone, is significantly increased, suggesting that indi-rect venodilatation occurs. When the same patients subsequently receive intravenous milrinone, both forearm vascular resistance and venous capacitance change substantially, reflecting the direct effects of the agent. Thus, it appears that reflex sympathetic withdrawal due to the positive inotropic action of the drugs on the heart may result in a small degree of venous dilatation, which may contribute to the small decreases in left-and right-heart filling pressures observed during intracoronary drug infusion. This effect is overshadowed by the more potent direct vasodilator effects of the agent in clinical practice.
The vasodilator effects of milrinone appear to differ significantly from those of angiotensinconverting enzyme inhibitors such as captopril. LeJemtel et al. 115 ' have compared the effects of milrinone and captopril, administered alone and together, on the systemic and regional haemodynamics of patients with moderate to severe congestive heart failure. Interestingly, they found that the haemodynamic improvement caused by the two agents was additive, so that the increase in stroke volume was greater with the two drugs together than with either agent alone. In contrast, they found that the regional blood flow effects of the two drugs were complementary. Captopril produced a substantial increase in renal blood flow, with relatively little change in leg muscular blood flow. Conversely, milrinone resulted in an improvement in leg blood flow when added to captopril, but appeared to have no further effect on renal blood flow. Thus, it may be anticipated that captopril will be most effective with regard to improving renal function, whereas in the short term, milrinone may be more effective with regard to improvement in exercise performance.
Conclusions
Milrinone differs significantly from pure inotropic or pure vasodilator agents. When compared to a pure vasodilator such as nitroprusside, milrinone exerts a greater haemodynamic effect, presumably reflecting its additional positive inotropic action. Clinically, this may allow milrinone to be tolerated by some patients whose response to vasodilators is limited by hypotension. Alternatively, milrinone's vasodilator action may help to offset the potentially adverse effects of positive inotropic stimulation on myocardial energetics. For example, Monrad et a/.' 16 ' and Grose et al. ' 17 ' have compared the effects of dobutamine and milrinone on left ventricular pump function and myocardial oxygen consumption in patients with congestive heart failure. Although both agents improved left ventricular pump function to a comparable degree, dobutamine increased myocardial oxygen consumption, whereas milrinone had no effect, presumably reflecting the ability of milrinone to decrease left ventricular loading conditions which are an important determinant of myocardial oxygen demand. Because the regional vasodilator effects of milrinone differ significantly from those of captopril, it is likely that the combined administration of milrinone and an angiotensin-converting enzyme inhibitor may have clinically important advantages over the use of either agent alone.
